title: Point: Fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status.
authors.affiliation: Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA. rossj@mail.amc.edu
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D003365:Costs and Cost Analysis; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000378:metabolism; D004943:Esophagogastric Junction / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000191:economics; D017404:In Situ Hybridization, Fluorescence / Q000191:economics; D058990:Molecular Targeted Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human